Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Illumina (NASDAQ: ILMN) and Tempus AI (NASDAQ: TEM) have announced a strategic collaboration to accelerate the clinical adoption of next-generation sequencing tests through AI-driven innovation. The partnership aims to combine Illumina's AI technologies with Tempus's multimodal data platform to enhance genomic algorithms and expand molecular profiling across various disease categories.
The collaboration focuses on developing evidence to standardize comprehensive genomic profiling and molecular testing beyond cancer, extending to cardiology, neurology, and immunology. This builds upon the companies' existing partnership in developing tools and assays for testing needs from preemptive screening through therapy selection.
The initiative addresses the current gap where patients often miss precision medicine benefits due to non-standardized molecular profiling across disease areas and regions. The partnership will leverage data analytics and sequencing technologies to improve patient outcomes and advance precision medicine research.
Tempus AI (NASDAQ: TEM) reported strong financial results for Q4 and full-year 2024. Q4 revenue grew 35.8% year-over-year to $200.7M, with Genomics revenue at $120.4M (30.6% growth) and Data and services at $80.2M (44.6% growth). Q4 gross profit increased 49.7% to $122.1M.
Full-year 2024 revenue reached $693.4M, up 30.4% YoY, with Genomics contributing $451.7M and Data services $241.6M. The company achieved 140% net revenue retention and ended with $940M in Total Remaining Contract Value. The net loss for 2024 was ($705.8M), including $547.7M in stock compensation expenses.
Following the Ambry Genetics acquisition in February 2025, Tempus increased its 2025 revenue guidance to $1.24B, projecting 79% annual growth. The company expects Adjusted EBITDA of $5M for 2025, marking a $110M improvement over 2024.
Tempus AI (NASDAQ: TEM) announced its first-time presentation of 4 research abstracts at the American College of Cardiology (ACC) Annual Meeting from March 29-31 in Chicago. The abstracts showcase the company's AI applications in cardiovascular care.
The research includes: (1) Machine learning models for predicting left ventricular systolic dysfunction, (2) EHR-integrated notifications for sudden cardiac arrest risk assessment, (3) Study on racial disparities in valvular heart disease from April 2019 to January 2024, and (4) Natural language processing application in cardiac transthyretin amyloidosis diagnosis.
According to Dr. Brandon Fornwalt, SVP of Cardiology at Tempus, the company aims to enable clinicians to provide improved, guideline-recommended care for patients with undiagnosed or undertreated cardiovascular disease through their AI-enabled insights and provider network.
Tempus AI (NASDAQ: TEM), a technology company focused on advancing precision medicine and patient care through artificial intelligence, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The conference is scheduled for April 7-10, 2025.
The company's Chief Financial Officer, Jim Rogers, will engage in a fireside discussion on Wednesday, April 9. The event will be accessible to viewers through a live webcast.
Tempus AI (NASDAQ: TEM) has announced the acquisition of Deep 6 AI, a leading AI-powered precision research platform. Deep 6 AI's network spans over 750 provider site locations and more than 30 million patients, which will significantly expand Tempus' existing infrastructure.
Deep 6 AI specializes in clinical trial optimization, patient recruitment acceleration, and real-world evidence generation. Their AI software matches patients to clinical trials by analyzing real-time structured and unstructured EMR data across various healthcare institutions, including academic medical centers, NCI-Designated Cancer Centers, and NCI Community Oncology Research Programs.
The acquisition aims to enhance Tempus' connectivity efforts and strengthen its ability to deploy critical applications like Next (for closing care gaps) and TIME (for matching patients to clinical trials).
Tempus AI (NASDAQ: TEM) reported strong Q4 2024 results with revenue increasing 35.8% year-over-year to $200.7 million. The company's Genomics segment generated $120.4 million (+30.6% YoY), while Data and services reached $80.2 million (+44.6% YoY).
Q4 gross profit grew 49.7% to $122.1 million, with net loss improving to ($13.0 million) from ($50.5 million) in Q4 2023. For full year 2024, revenue increased 30.4% to $693.4 million, with Genomics contributing $451.7 million and Data services $241.6 million.
The company completed the Ambry Genetics acquisition on February 3, 2025, and received FDA approval for xT CDx diagnostic device with a $4,500 reimbursement rate. Tempus projects 2025 revenue of $1.24 billion (+79% growth) and expects positive Adjusted EBITDA of $5 million, marking a $110 million improvement over 2024.
Tempus AI (NASDAQ: TEM) and Genialis have announced a multi-year collaboration to develop new RNA-based algorithms for cancer treatment. Genialis will utilize Tempus' multimodal dataset to validate their AI foundation model, the Genialis™ Supermodel, which was developed using ~1 million RNA-sequencing samples.
Through this partnership, Genialis gains access to Tempus' Lens analytics platform, providing de-identified multimodal patient records to validate biomarker signatures. Tempus receives rights to evaluate and potentially license Genialis-developed algorithms for their xR platform.
The collaboration has already yielded results with Genialis™krasID, the first commercial algorithm predicting patient response to KRAS-targeted therapies across cancer types. This algorithm, validated using Tempus' data, effectively stratifies patients into response groups based on their likelihood of treatment success.
Tempus AI (NASDAQ: TEM) has announced its participation in the TD Cowen 45th Annual Health Care Conference, scheduled for March 3-5, 2025, in Boston, MA. The company's Chief Financial Officer, Jim Rogers, will engage in a fireside discussion on Monday, March 3. The event will be accessible to viewers through a live webcast.
Tempus, which specializes in leveraging artificial intelligence for precision medicine and patient care advancement, will use this platform to share insights about their technology and healthcare initiatives.
Ares Management (NYSE: ARES) has expanded its debt financing for Tempus AI (NASDAQ: TEM) with an additional $300 million, bringing the total debt package to $560 million. The new financing supports Tempus' recent acquisition of Ambry Genetics, which closed on February 3, 2025.
Tempus, founded in 2015, specializes in implementing AI solutions in healthcare, focusing on clinical care and research products. The company's integrated business model includes patient sequencing, data collection through licensing and analytical tools, and diagnostic testing insights across oncology, cardiology, pathology, and radiology.
This financing demonstrates Ares' capability to provide scalable capital to both non-sponsor-backed and sponsor-backed borrowers, with Ares expressing confidence in Tempus' growth strategy and the strategic acquisition of Ambry.
Tempus AI (NASDAQ: TEM) has announced its participation in the upcoming Morgan Stanley Technology, Media & Telecom Conference scheduled for March 3-6, 2025, in San Francisco, CA. The company's Founder and CEO, Eric Lefkofsky, will engage in a fireside discussion on March 3, 2025. The event will be accessible to viewers through a live webcast.
Tempus, which specializes in leveraging AI technology for precision medicine and patient care advancement, will use this platform to share insights about their operations and innovations. This participation represents an important opportunity for investors and stakeholders to gain direct insights into the company's strategies and developments.